These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24416293)

  • 1. The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania.
    Mori AT; Kaale EA; Ngalesoni F; Norheim OF; Robberstad B
    PLoS One; 2014; 9(1):e84824. PubMed ID: 24416293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision criteria for selecting essential medicines and their connection to guidelines: an interpretive descriptive qualitative interview study.
    Piggott T; Moja L; Akl EA; Lavis JN; Cooke G; Kredo T; Hogerzeil HV; Huttner B; Alonso-Coello P; Schünemann H
    J Clin Epidemiol; 2023 Feb; 154():146-155. PubMed ID: 36584732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review.
    Mori AT; Robberstad B
    BMC Med Inform Decis Mak; 2012 Sep; 12():110. PubMed ID: 23016739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introducing health technology assessment in Tanzania.
    Surgey G; Chalkidou K; Reuben W; Suleman F; Miot J; Hofman K
    Int J Technol Assess Health Care; 2020 Apr; 36(2):80-86. PubMed ID: 31402790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of essential medicines for South Africa - an analysis of in-depth interviews with national essential medicines list committee members.
    Perumal-Pillay VA; Suleman F
    BMC Health Serv Res; 2017 Jan; 17(1):17. PubMed ID: 28061899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the decision making process of selection of medicines in the private sector in South Africa - lessons for low-middle income countries.
    Perumal-Pillay VA; Suleman F
    J Pharm Policy Pract; 2020; 13():17. PubMed ID: 32477570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of government agencies and other actors in influencing access to medicines in three East African countries.
    Odoch WD; Dambisya Y; Peacocke E; Sandberg KI; Hembre BSH
    Health Policy Plan; 2021 Apr; 36(3):312-321. PubMed ID: 33569583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to develop cost-conscious guidelines.
    Eccles M; Mason J
    Health Technol Assess; 2001; 5(16):1-69. PubMed ID: 11427188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaching beyond the review of research evidence: a qualitative study of decision making during the development of clinical practice guidelines for disease prevention in healthcare.
    Richter Sundberg L; Garvare R; Nyström ME
    BMC Health Serv Res; 2017 May; 17(1):344. PubMed ID: 28490325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision making about healthcare-related tests and diagnostic test strategies. Paper 5: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision making.
    Mustafa RA; Wiercioch W; Ventresca M; Brozek J; Schünemann HJ;
    J Clin Epidemiol; 2017 Dec; 92():47-57. PubMed ID: 28917629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative Evidence Synthesis (QES) for Guidelines: Paper 2 - Using qualitative evidence synthesis findings to inform evidence-to-decision frameworks and recommendations.
    Lewin S; Glenton C; Lawrie TA; Downe S; Finlayson KW; Rosenbaum S; Barreix M; Tunçalp Ö
    Health Res Policy Syst; 2019 Aug; 17(1):75. PubMed ID: 31391119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
    Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
    Fertil Steril; 2018 Aug; 110(3):364-379. PubMed ID: 30033227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders.
    Jarvis JD; Murphy A; Perel P; Persaud N
    CMAJ; 2019 Oct; 191(40):E1093-E1099. PubMed ID: 31591095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
    PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
    Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
    J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List.
    Liu W; Shi L; Sawhney M; Gu X; Chen Y
    BMC Health Serv Res; 2019 Feb; 19(1):112. PubMed ID: 30744609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.